Abstract
A 57-year-old man with stage IIIB malignant melanoma of unknown primary presented for pretherapy FDG PET/CT that demonstrated metastatic left cervical lymph node with no other site of involvement. Following left neck dissection, nivolumab was initiated. Follow-up FDG PET/CT 3 months after initiation of nivolumab demonstrated extensive radiotracer-avid chest lymphadenopathy and multiple bone lesions. Ultrasound-guided endobronchial biopsy of the mediastinal lymph nodes demonstrated sarcoidosis.
Original language | English (US) |
---|---|
Pages (from-to) | E519-E521 |
Journal | Clinical nuclear medicine |
Volume | 44 |
Issue number | 9 |
DOIs | |
State | Published - Sep 1 2019 |
Keywords
- Malignant melanoma
- Nivolumab
- Osseous sarcoidosis
- Pulmonary sarcoidosis
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging